lenalidomide has been researched along with Experimental Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Chen, Y; Deng, D; Liu, K; Shi, M; Tang, M; Yang, T; Yuan, X | 1 |
| Bartlett, JB; Cai, Z; Qian, Z; Sun, L; Wang, H; Wang, M; Yi, Q; Zhang, L | 1 |
| Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA | 1 |
| Alexander, HR; Blansfield, JA; Caragacianu, D; Libutti, SK; Lorang, D; Morita, SY; Muller, G; Royal, RE; Schafer, P; Stirling, D; Tangrea, MA | 1 |
4 other study(ies) available for lenalidomide and Experimental Neoplasms
| Article | Year |
|---|---|
Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Humans; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Structure; Mutation; Neoplasms, Experimental; Protein Kinase Inhibitors; Proteolysis; Small Molecule Libraries; Structure-Activity Relationship | 2022 |
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blood Cells; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Synergism; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; MAP Kinase Kinase 4; Mice; Mice, SCID; Neoplasms, Experimental; Phosphorylation; Rituximab; Thalidomide | 2009 |
Initial testing of lenalidomide by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Child; Female; Humans; Lenalidomide; Mice; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Endothelial Cells; Female; Fluorescent Antibody Technique; Humans; Indoles; Lenalidomide; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Rats; Sunitinib; Thalidomide; Xenograft Model Antitumor Assays | 2008 |